Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Shares Outstanding (Weighted Average): 2017-2024

Historic Shares Outstanding (Weighted Average) for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to $61.5 million.

  • Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) rose 8.65% to $66.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.4 million, marking a year-over-year increase of 8.65%. This contributed to the annual value of $61.5 million for FY2024, which is 3.99% up from last year.
  • As of FY2024, Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $61.5 million, which was up 3.99% from $59.1 million recorded in FY2023.
  • Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $61.5 million during FY2024, with a 5-year trough of $44.2 million in FY2020.
  • In the last 3 years, Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $59.1 million in 2023 and averaged $59.0 million.
  • Data for Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY increased of 13.72% (in 2021) over the last 5 years.
  • Over the past 5 years, Rhythm Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $44.2 million in 2020, then increased by 13.72% to $50.3 million in 2021, then grew by 12.10% to $56.3 million in 2022, then climbed by 4.88% to $59.1 million in 2023, then increased by 3.99% to $61.5 million in 2024.